Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to allow it to ...

Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

When drug companies manipulate the system to increase profits, patients suffer. Arizona Attorney General Kris Mayes is right to take GlaxoSmithKline to court over its decision to discontinue Flovent, ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

Highlights,GSK (NYSE:GSK) remains a key player in pharmaceuticals with a strong focus on research and development.,The ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise ...

Shares of GSK PLC GSK advanced 1.56% to £14.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.77% to 8,767.80. GSK PLC ...